Precision-Driven Advancements in Cancer Treatment: A Review of Emerging Therapies and Personalized Approaches
Precision-Driven Advancements in Cancer Treatment
Keywords:
cancer therapeutics, precision oncology, Nano medicine, cellular immunotherapyAbstract
Cancer remains a significant global health challenge despite advances in research and treatment. In 2023 alone, statistics documented nearly 19.3 million new diagnoses and 10 million fatalities. While conventional therapies like surgery, chemotherapy, and radiation have demonstrably improved survival outcomes, they often result in systemic side effects, particularly in advanced malignancies. In recent years, the field of oncology has placed more focus on specific molecular and cellular mechanisms that trigger tumor growth. Several treatments, such as targeted therapy and immunotherapy, have evolved from these advancements and work to enhance immune-mediated tumor recognition and destruction while limiting the amount of damage to normal tissue. Furthermore, using drugs like rosiglitazone and MEK inhibitors to cause cancer cells to transdifferentiate into benign adipocyte-like cells represents a novel approach to non-lethal cancer control. Chimeric antigen receptor (CAR) T-cell therapy has demonstrated significant clinical success in treating blood malignancies. In contrast, oncolytic therapy uses genetically modified viruses to infect and kill cancerous cells and stimulate antitumor immunity. Non-invasive technologies like histotripsy use focused ultrasound waves to mechanically disrupt cancerous cells. This review study summarizes the latest innovative developments in oncology by incorporating all of the most recent promising techniques currently available. A new era in cancer care is being signaled by these developments, which not only assist patients in responding better to cancer treatment but also enhance their quality of life. More technological and scientific advancements will be required to give patients new, creative cancer control methods that are more precise and less toxic.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209-249. https://doi.org/10.3322/caac.21660
Liu B, Zhou H, Tan L, Siu KTH, Guan XY, et al. Exploring treatment options in cancer: Tumor treatment strategies. Signal Transduction and Targeted Therapy. 2024;9(1):175. https://doi.org/10.1038/s41392-024-01856-7
Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature Medicine. 2018;24(5):541-550. https://doi.org/10.1038/s41591-018-0014-x
Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: Treating cancer with specificity. EurJPharmacol.2018;834:188-196.
https://doi.org/10.1016/j.ejphar.2018.07.034
Wang Y, Tang SC. Targeted cancer therapy: A comprehensive review of strategies in drug development. Critical Reviews in Oncology/Hematology. 2026;223:105349. https://doi.org/10.1016/j.critrevonc.2026.105349
Wang J, Zhang Q, Cao Y, et al. Precision theranostics in oncology: Integrating antibody-drug conjugates, radioimmunotherapy, and immuno-PET for adaptive cancer care. Discover Oncology. 2026;17(1):974. https://doi.org/10.1007/s12672-026-01974-2
Brudno JN, Maus MV, Hinrichs CS. CAR T cells and T-cell therapies for cancer: A translational science review. JAMA. 2024;332(22):1924-1935.
https://doi.org/10.1001/jama.2024.19462
Kwak D, Hammarström LGJ, Haraldsson M, Ernfors P. Glioblastoma cytotoxicity conferred through dual disruption of endolysosomal homeostasis by Vacquinol-1. Neuro-OncologyAdvances.2021;3(1):vdab152.
https://doi.org/10.1093/noajnl/vdab152
Hirsch LR, Stafford RJ, Bankson JA, Sershen SR, Rivera B, Price RE, et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proceedings of the National Academy of Sciences of the United States of America. 2003;100(23):13549-13554.
https://doi.org/10.1073/pnas.2232479100
Su C, Ren X, Nie F, Li T, Lv W, Li H, et al. Current advances in ultrasound-combined nanobubbles for cancer-targeted therapy: A review of the current status and future perspectives.RSCAdvances.2021;11(21):12915-12928.
https://doi.org/10.1039/D0RA08727K
Perera RH, de Leon A, Wang X, Wang Y, Ramamurthy G, Peiris P, et al. Real-time ultrasound molecular imaging of prostate cancer with PSMA-targeted nanobubbles. Nanomedicine, (2020); 28: 102213. https://doi.org/10.1016/j.nano.2020.102213
Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, Kitui SK, Manyazewal T. New approaches and procedures for cancer treatment: Current perspectives.SAGEOpenMedicine.2021;9:20503121211034366.
https://doi.org/10.1177/20503121211034366
Díaz-Alejo JF, González Gómez I, Earl J. Ultrasounds in cancer therapy: A summary of their use and unexplored potential. Oncology Reviews. 2022;16(1):531.
https://doi.org/10.4081/oncol.2022.531
Dheyab MA, Abdul Aziz A, Moradi Khaniabadi P, Jameel MS, Oladzadabbasabadi N, Abdul Rahman A, et al. Gold nanoparticles-based photothermal therapy for breast cancer. Photodiagnosis and Photodynamic Therapy. 2023;42:103312. https://doi.org/10.1016/j.pdpdt.2023.103312
Edwards IA, De Carlo F, Sitta J, Varner W, Howard CM, Claudio PP. Enhancing targeted therapy in breast cancer by ultrasound-responsive nanocarriers. International Journal of Molecular Sciences. 2023;24(6):5474.
https://doi.org/10.3390/ijms24065474
Liu N, Fan F. Advances in nanobubbles for cancer theranostics: Delivery, imaging and therapy. Biochemical Pharmacology. 2024;226:116341.
https://doi.org/10.1016/j.bcp.2024.116341
Ishay-Ronen D, Diepenbruck M, Kalathur RKR, Sugiyama N, Tiede S, Ivanek R, et al. Gain Fat-Lose Metastasis: Converting Invasive Breast Cancer Cells into Adipocytes Inhibits Cancer Metastasis. Cancer Cell. 2019;35(1):17-32.e6.
https://doi.org/10.1016/j.ccell.2018.12.002
Ben-Yishay R, Globus O, Balint-Lahat N, Arbili-Yarhi S, Bar-Hai N, Bar V, et al. Class effect unveiled: PPARγ agonists and MEK inhibitors in cancer cell differentiation. Cells. 2024;13(17):1506. https://doi.org/10.3390/cells13171506
Suryavanshi A, Vandana, Shukla YK, Kumar V, Gupta P, Asati V, et al. MEK inhibitors in oncology: A patent review and update (2016–present). Expert Opinion on Therapeutic Patents.2024;34(10):963-1007.
https://doi.org/10.1080/13543776.2024.2403634
Zhao J, Qian H, An Y, Chu L, et al. PPARγ and C/EBPα enable adipocyte differentiation upon inhibition of histone methyltransferase PRC2 in malignant tumors. Journal of Biological Chemistry. 2024;300(10):107765. https://doi.org/10.1016/j.jbc.2024.107765
Shan KS, Rehman TU, Ivanov S, Domingo G, Raez LE. Molecular targeting of the BRAF proto-oncogene/mitogen-activated protein kinase (MAPK) pathway across cancers. International Journal of Molecular Sciences. 2024;25(1):624. https://doi.org/10.3390/ijms25010624
Hamidi M, Zarrin A, Foroozesh M, Mohammadi-Samani S. Targeted cancer therapy with antibody-decorated nanomedicines. Journal of Controlled Release. 2018;294:130-144. https://doi.org/10.1016/j.jconrel.2018.12.005
Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: Advances and future directions. Nature Reviews Drug Discovery. 2023;22(2):101-126. https://doi.org/10.1038/s41573-022-00579-0
Yu G, Yung BC, Zhou Z, Mao Z, Chen X. Artificial molecular machines in nanotheranostics. ACS Nano. 2018;12(1):7-12. https://doi.org/10.1021/acsnano.7b07011
Pessach I, Nagler A. Leukapheresis for CAR-T cell production and therapy. Transfusion and Apheresis Science, (2023); 62(6): 103828. https://doi.org/10.1016/j.transci.2023.103828
Li R, Qian J, Zhu X, Tao T, Zhou X. Nanomolecular machines: Pioneering precision medicine for neoplastic diseases through advanced diagnosis and treatment. Biochimica et Biophysica Acta - Molecular Basis of Disease. 2024;1870(8):167486. https://doi.org/10.1016/j.bbadis.2024.167486
Choudhery MS, Arif T, Mahmood R, Harris DT. CAR-T-cell-based cancer immunotherapies: Potentials, limitations, and future prospects. Journal of Clinical Medicine. 2024;13(11):3202. https://doi.org/10.3390/jcm13113202
Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cellular & Molecular Immunology. (2024); 21(10): 1089-1108. https://doi.org/10.1038/s41423-024-01207-0
Xu Z, Khokhlova TD, Cho CS, Khokhlova VA. Histotripsy: A method for mechanical tissue ablation with ultrasound. Annual Review of Biomedical Engineering. 2024;26:141-167. https://doi.org/10.1146/annurev-bioeng-111123-114942
Li F, Li Z, Wei C, Xu L, Liang Y, Yan J, et al. Application of hydrogels for targeting cancer stem cells in cancer treatment. Biomedicine & Pharmacotherapy. 2024;180:117486. https://doi.org/10.1016/j.biopha.2024.117486
Worlikar T, Vlaisavljevich E, Gerhardson T, Greve J, Hall TL, Shi J, et al. Histotripsy and the immune response in cancer. Cancers. 2022;14(3):658. https://doi.org/10.3390/cancers14030658
Xu Z, Hall TL, Vlaisavljevich E, Lee FT Jr. Histotripsy: The first noninvasive, non-ionizing, non-thermal ablation technique based on ultrasound. International Journal of Hyperthermia. 2021;38(1):561-575. https://doi.org/10.1080/02656736.2021.1909544
Singh S, Abu-Zaid A, Jin H, Fang J, Wu Q, Wang T, et al. Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma. Science Translational Medicine. 2022;14(653):eabq2096. https://doi.org/10.1126/scitranslmed.abq2096
Ruger LN, Hay AN, Vickers ER, Coutermarsh-Ott SL, Gannon JM, Covell HS, et al. Characterizing the ablative effects of histotripsy for osteosarcoma: In vivo study in dogs. Cancers. 2023;15(3):741. https://doi.org/10.3390/cancers15030741
Wang LL, Gao Y, Feng Z, Mooney DJ, Mitragotri S. Designing drug delivery systems for cell therapy. Nature Reviews Bioengineering. 2024;2:944-959. https://doi.org/10.1038/s44222-024-00228-6
Yu Y, Tao Y, Ma J, Li J, Song Z. Targeting the tumor microenvironment with mesenchymal stem cells-based delivery approach for efficient delivery of anticancer agents: An updated review. Biochemical Pharmacology, (2025); 232: 116725. https://doi.org/10.1016/j.bcp.2024.116725
Tanaka Y, Tsuruma A, Ishii M, Kawai K, Yasuda K, Sato K, et al. Double-network hydrogel induces cancer stem cell-like phenotypes in cancer cells. Communications Biology. 2023;6(1):1080. https://doi.org/10.1038/s42003-023-05460-9
Gutwillig A, Keren L, Danon T, et al. Cancer cells induce a reversible cell-in-cell state to evade immune attack. Nature. 2023;618(7964):766-776. https://doi.org/10.1038/s41586-023-06123-5
Mao X, Wu S, Huang D, Li C. Complications and comorbidities associated with antineoplastic chemotherapy: Rethinking drug design and delivery for anticancer therapy. Acta Pharmaceutica Sinica B. 2024;14(10):4052-4080. https://doi.org/10.1016/j.apsb.2024.03.006
Russell SJ, Barber GN. Oncolytic viruses as antigen-agnostic cancer vaccines. Cancer Cell. 2018;33(4):599-605. https://doi.org/10.1016/j.ccell.2018.03.011
Hoffmann E, Masthoff M, Kunz WG, Seidensticker M, Bobe S, Gerwing M, et al. Multiparametric MRI for characterization of the tumour microenvironment. Nature Reviews Clinical Oncology, (2024); 21(6): 428-448. https://doi.org/10.1038/s41571-024-00891-1
Zeng M, Zhang W, Li Y, et al. Harnessing adenovirus in cancer immunotherapy: Evoking cellular immunity and targeting delivery in a cell-specific manner. Biomarker Research. 2024;12:36. https://doi.org/10.1186/s40364-024-00637-0
Yan Z, Zhang Z, Chen Y, Xu J, Wang J, Wang Z. Enhancing cancer therapy: The integration of oncolytic virus therapy with diverse treatments. Cancer Cell International. 2024;24(1):242. https://doi.org/10.1186/s12935-024-03424-z
Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, et al. Analysis of nanoparticle delivery to tumours. Nature Reviews Materials. 2016;1:16014. https://doi.org/10.1038/natrevmats.2016.14
Paredes R, Borea R, Drago F, Russo A, Nigita G, Rolfo C. Genetic drivers of tumor microenvironment and immunotherapy resistance in non-small cell lung cancer: The role of KEAP1, SMARCA4, and PTEN mutations. Journal for ImmunoTherapy of Cancer. 2025;13(8):e012288.https://doi.org/10.1136/jitc-2025-012288
Xiao D, Zhang H, Liu Y, Li Y, Li G, Ning Y, et al. Oncolytic viruses: Advanced strategies in cancer therapy. Signal Transduction and Targeted Therapy. 2026;11:45. https://doi.org/10.1038/s41392-025-02343-3
García-López V, Chen F, Nilewski LG, Duret G, Aliyan A, Kolomeisky AB, et al. Molecular machines open cell membranes. Nature. 2017;548(7669):567-572. https://doi.org/10.1038/nature23657
Subbiah V, Gouda MA, Ryll B, Burris HA III, Kurzrock R. The evolving landscape of tissue-agnostic therapies in precision oncology. CA: A Cancer Journal for Clinicians. 2024;74(5):433-452. https://doi.org/10.3322/caac.21891
Wang X, Zhang H, Chen X, Wu C, Ding K, Sun G, et al. Overcoming tumor microenvironment obstacles: Current approaches for boosting nanodrug delivery. Acta Biomaterialia. 2023;166:42-68. https://doi.org/10.1016/j.actbio.2023.05.043
Xu Z, Qiu HW, Xu Y, Wang J, Cao F, Wang Y, et al. Fluorinated lipid nanoparticles enable in vivo CAR-macrophage therapy in solid tumor and enhance anti-PD-L1 immunotherapy. Biomaterials. 2026;331:124093. https://doi.org/10.1016/j.biomaterials.2025.124093
